NCT06678126 Adaptive Versus Non-adaptive Radiotherapy and 2 Bladder Filling Instructions for Patients With Intermediate or High Risk Localized Prostate Cancer (ARP)
| NCT ID | NCT06678126 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Scott Tyldesley |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 104 participants |
| Start Date | 2026-01-16 |
| Primary Completion | 2033-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 104 participants in total. It began in 2026-01-16 with a primary completion date of 2033-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is being done to compare the side effects between two different radiation techniques, standard non-adaptive radiation therapy vs. daily adaptive radiation therapy and also comparing two different bladder filling instructions to find out if customized bladder instructions may lead to better treatment outcomes.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 * Pathological diagnosis of a primary prostate adenocarcinoma * NCCN Intermediate or high risk localized prostate cancer and clinically N0 and M0 by conventional imaging * Intermediate: one or more of cT2b-T2c, PSA 10-20, or Gleason Group 2 or 3 * High: one or more of: cT3a, PSA \> 20, or Gleason Group 4 or 5. * Consented to RT with moderate hypofractionated RT to pelvic nodes (44 Gy) and prostate (60Gy) in 20 fractions using standard BC Cancer regimen * Able to complete BC Cancer POSI questionnairesWilling to attend adaptive treatment slot timing as required by treating centre. * Willing and able to have regular per protocol follow up and blood work * Feasible to start protocol treatment within 120 calendar days of participant enrolment * Continent of urine (or able to maintain continence with penile clamp/cuff during RT as needed) and able to follow bladder filling instructions. * Baseline IPSS score \< 20 at time of enrolment. * ECOG performance Status : 0-2. * Nodal risk ≥ 20% using the Memorial Sloan Kettering Nodal Risk Nomogram (https://www.mskcc.org/nomograms/prostate/pre\_op). * Negative for bone metastases on bone scan within 3 months of enrolment * No involved nodes on Abdomen and pelvic CT or pelvic MRI within 3 months of enrolment. Exclusion Criteria: * Indwelling urinary catheter. * Hip prosthesis * Prior pelvic radiotherapy * Unable to lie still on RT treatment couch for more than 30 minutes * Clinical T3b or T4 tumours * Prior transurethral resection of prostate or radical prostatectomy * Presence of a pelvic kidney. * Prior pelvic radiotherapy. * Significant urinary incontinence: ie \> 1 soaked, or 2 non-soaked pads per day. * Inflammatory bowel disease, systemic lupus erythematosis, scleroderma, or other connective tissue disorders other than rheumatoid arthritis. * Metastatic disease identified on staging investigations. * Any other serious intercurrent illness or medical condition judged by the local investigator to compromise the participant's safety, preclude safe administration of the planned protocol treatment, or prevent the participant from being managed according to the protocol guidelines * Potentially fertile patient who are unwilling to employ highly effective contraception
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06678126 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06678126 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06678126 currently recruiting?
Yes, NCT06678126 is actively recruiting participants. Contact the research team at armin.mardani@bccancer.bc.ca for enrollment information.
Where is the NCT06678126 trial being conducted?
This trial is being conducted at Vancouver, Canada.
Who is sponsoring the NCT06678126 clinical trial?
NCT06678126 is sponsored by Scott Tyldesley. The trial plans to enroll 104 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.